CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on GLP-1 medications for weight loss than clients who did not adopt the program. The program also has a ...

As of Feb. 1, 2025, the CVS Weight Management program is now available to more than 3.5 million CVS Caremark plan members. Industry Prospects Favoring CVS Per a research report, the global weight ...

CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on GLP-1 medications for weight-loss, compared to those clients who did not adopt the program. 1 The program ...

CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on GLP-1 medications for weight-loss, compared to those clients who did not adopt the program. 1 The program ...

Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”), CVS Caremark, will list Wegovy — the flagship GLP-1-based weight loss medication from Novo Nordisk NVO — on its largest ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success. The company will no ...